Adolor And GlaxoSmithKline Announce FDA Approval Of Entereg(R) (alvimopan) For The Management Of Postoperative Ileus (POI)
Adolor Corporation (Nasdaq:ADLR) and GlaxoSmithKline (NYSE:GSK) announced that the U.S. Food and Drug Administration has approved EnteregŪ (alvimopan) capsules to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery. Postoperative ileus (POI) is a condition that affects almost all patients undergoing this type of surgery and can cause significant discomfort in addition to prolonging hospital stays for patients.
More: continued here